Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical
 Hodgkin Lymphoma.
This study will include a retrospective and prospective observational database analysis.
Inclusion Criteria:

 -  Age greater than or equal to18 years;

 -  First allogeneic HCT for cHL;

 -  Patients with prior autologous HCT for cHL;

 -  Any conditioning regimen, graft source or donor type.

 -  For the primary analysis additional criterion includes prior exposure to nivolumab for
 treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used
 alone or in combination with other agents and used as the last line of therapy prior
 to an allogeneic HCT with the interval between the last dose of nivolumab and start of
 the conditioning regimen no longer than 12 months.

 Exclusion Criteria:

 -  Patients with nodular lymphocyte-predominant HL

 -  Previous chimeric antigen receptor T-cell therapy or other genetically modified
 cellular product